NCT02536508: A reported trial by Pearl Therapeutics, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02536508 |
|---|---|
| Title | A Randomized, Double-Blind, Parallel-Group, 52-Week, Chronic-Dosing, Multi-Center Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 10, 2015 |
| Completion date | Sept. 12, 2017 |
| Required reporting date | Sept. 12, 2020, midnight |
| Actual reporting date | April 22, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |